Reduced Next-Day Sedation with Extended Release Formulations

Pharmacokinetic and Clinical Evidence

• The American Academy of Sleep Medicine recognizes that extended release formulations, such as zolpidem ER, maintain therapeutic effects while reducing next-day impairment 1, 2
• The FDA recommends lower starting doses for extended-release zolpidem to reduce next-day sedation, with a recommended starting dose of 6.25 mg 2
• Extended release formulations provide more consistent plasma levels throughout the dosing period, reducing the "hangover effect" commonly associated with sedating medications 1, 3

Patient Factors and Considerations

• Individual patient factors, including age, hepatic function, and concomitant medications, can affect the metabolism of quetiapine and influence sedation levels, as noted by the American College of Clinical Pharmacology 4, 5